Biotech Values

[biomaven0]

>>Ponatinib Dose Modification

That might reassure the FDA some. Interesting that higher platelet counts were a significant risk factor in their model (but unclear if these were actually high in an absolute sense, or just relatively high vs. low counts in other patients).

Also interesting that the MD Andersen front line trial shows not a hint of cardiovascular issues except for some hypertension in a small number of patients.

Peter